Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 106 | 2024 | 21206 | 3.540 |
Why?
|
Receptor, erbB-2 | 39 | 2024 | 2603 | 2.480 |
Why?
|
Quinolines | 14 | 2024 | 772 | 1.720 |
Why?
|
Medical Oncology | 12 | 2023 | 2346 | 1.630 |
Why?
|
Neoplasms | 24 | 2024 | 22371 | 1.320 |
Why?
|
Vulnerable Populations | 6 | 2024 | 718 | 1.320 |
Why?
|
Receptors, Progesterone | 13 | 2022 | 1160 | 1.180 |
Why?
|
Nitriles | 4 | 2015 | 980 | 1.130 |
Why?
|
Receptors, Estrogen | 14 | 2021 | 2253 | 1.110 |
Why?
|
Quinazolines | 10 | 2016 | 1373 | 1.070 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2021 | 1536 | 0.990 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 37 | 2024 | 11878 | 0.960 |
Why?
|
Bone Density Conservation Agents | 4 | 2022 | 797 | 0.890 |
Why?
|
Aromatase Inhibitors | 4 | 2017 | 519 | 0.830 |
Why?
|
Chemotherapy, Adjuvant | 31 | 2023 | 3556 | 0.820 |
Why?
|
Triazoles | 3 | 2015 | 904 | 0.810 |
Why?
|
Conflict of Interest | 5 | 2016 | 556 | 0.770 |
Why?
|
Clinical Trials as Topic | 11 | 2021 | 8054 | 0.690 |
Why?
|
Bone Neoplasms | 4 | 2022 | 2565 | 0.630 |
Why?
|
Health Services Accessibility | 8 | 2019 | 5520 | 0.610 |
Why?
|
Aniline Compounds | 2 | 2014 | 1094 | 0.610 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2023 | 9419 | 0.610 |
Why?
|
Industry | 3 | 2016 | 362 | 0.570 |
Why?
|
Delivery of Health Care | 8 | 2023 | 5367 | 0.570 |
Why?
|
Health Care Costs | 4 | 2014 | 3239 | 0.570 |
Why?
|
Neoadjuvant Therapy | 8 | 2023 | 2907 | 0.550 |
Why?
|
Financing, Personal | 1 | 2019 | 310 | 0.540 |
Why?
|
Androstadienes | 3 | 2017 | 348 | 0.530 |
Why?
|
Disease-Free Survival | 22 | 2023 | 6847 | 0.520 |
Why?
|
Hormones | 4 | 2024 | 866 | 0.510 |
Why?
|
Healthcare Disparities | 7 | 2024 | 3415 | 0.500 |
Why?
|
Protein Kinase Inhibitors | 12 | 2023 | 5703 | 0.500 |
Why?
|
Diphosphonates | 4 | 2022 | 634 | 0.480 |
Why?
|
Immunoconjugates | 4 | 2024 | 975 | 0.480 |
Why?
|
Antineoplastic Agents | 14 | 2021 | 13676 | 0.480 |
Why?
|
Female | 119 | 2024 | 397192 | 0.470 |
Why?
|
Patient Participation | 4 | 2019 | 1447 | 0.460 |
Why?
|
Humans | 148 | 2024 | 768166 | 0.450 |
Why?
|
Health Care Rationing | 2 | 2014 | 435 | 0.440 |
Why?
|
Paclitaxel | 10 | 2023 | 1733 | 0.440 |
Why?
|
Professional Practice | 2 | 2016 | 314 | 0.440 |
Why?
|
Camptothecin | 4 | 2024 | 600 | 0.420 |
Why?
|
Travel | 1 | 2019 | 805 | 0.420 |
Why?
|
Peer Review, Research | 1 | 2015 | 344 | 0.410 |
Why?
|
Research | 2 | 2022 | 1979 | 0.370 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 905 | 0.370 |
Why?
|
Mastectomy, Segmental | 6 | 2020 | 974 | 0.360 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 1099 | 0.350 |
Why?
|
Drug Industry | 1 | 2016 | 791 | 0.340 |
Why?
|
Private Sector | 1 | 2013 | 396 | 0.340 |
Why?
|
Geriatrics | 1 | 2014 | 394 | 0.330 |
Why?
|
Ontario | 2 | 2022 | 403 | 0.330 |
Why?
|
Patients | 3 | 2013 | 908 | 0.320 |
Why?
|
Neoplasm Staging | 20 | 2021 | 11244 | 0.310 |
Why?
|
Quality of Life | 11 | 2024 | 13490 | 0.300 |
Why?
|
Physician's Role | 1 | 2014 | 925 | 0.290 |
Why?
|
Minority Groups | 2 | 2023 | 1216 | 0.280 |
Why?
|
Practice Guidelines as Topic | 2 | 2022 | 7454 | 0.280 |
Why?
|
Survivors | 2 | 2016 | 2381 | 0.280 |
Why?
|
Quality Assurance, Health Care | 2 | 2014 | 2176 | 0.270 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2885 | 0.270 |
Why?
|
Medically Uninsured | 1 | 2012 | 840 | 0.270 |
Why?
|
Middle Aged | 64 | 2024 | 223492 | 0.260 |
Why?
|
Postmenopause | 3 | 2014 | 2518 | 0.260 |
Why?
|
Health Care Reform | 2 | 2014 | 1256 | 0.260 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2018 | 1188 | 0.260 |
Why?
|
Mastectomy | 8 | 2020 | 1861 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3238 | 0.250 |
Why?
|
Bone and Bones | 1 | 2016 | 2589 | 0.240 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3239 | 0.240 |
Why?
|
Aged | 49 | 2024 | 171504 | 0.240 |
Why?
|
Financial Support | 2 | 2016 | 116 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.230 |
Why?
|
Pain | 2 | 2017 | 5100 | 0.220 |
Why?
|
Brain Neoplasms | 6 | 2024 | 9118 | 0.220 |
Why?
|
United States | 18 | 2022 | 73039 | 0.210 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2830 | 0.210 |
Why?
|
Cross-Cultural Comparison | 1 | 2006 | 638 | 0.210 |
Why?
|
Disclosure | 2 | 2008 | 755 | 0.210 |
Why?
|
Cost of Illness | 3 | 2022 | 1951 | 0.210 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2023 | 565 | 0.200 |
Why?
|
Physicians | 3 | 2016 | 4598 | 0.200 |
Why?
|
Economics, Medical | 1 | 2022 | 112 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 879 | 0.200 |
Why?
|
Tamoxifen | 1 | 2006 | 966 | 0.190 |
Why?
|
Prognosis | 12 | 2024 | 30010 | 0.190 |
Why?
|
Patient Acceptance of Health Care | 4 | 2018 | 3231 | 0.190 |
Why?
|
Mammography | 4 | 2010 | 2433 | 0.190 |
Why?
|
Neoplasm Metastasis | 8 | 2021 | 4912 | 0.190 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2020 | 952 | 0.180 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 1015 | 0.180 |
Why?
|
Cost-Benefit Analysis | 2 | 2013 | 5536 | 0.180 |
Why?
|
Community Health Centers | 1 | 2024 | 469 | 0.180 |
Why?
|
Patient Selection | 4 | 2023 | 4260 | 0.170 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13586 | 0.170 |
Why?
|
Decision Support Techniques | 2 | 2012 | 2008 | 0.170 |
Why?
|
Patient Education as Topic | 2 | 2011 | 2337 | 0.170 |
Why?
|
Meningeal Carcinomatosis | 1 | 2020 | 65 | 0.170 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2000 | 106 | 0.170 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2020 | 354 | 0.170 |
Why?
|
Mass Screening | 5 | 2020 | 5458 | 0.160 |
Why?
|
BRCA2 Protein | 2 | 2024 | 802 | 0.160 |
Why?
|
Decision Making | 5 | 2014 | 3953 | 0.160 |
Why?
|
Adult | 46 | 2024 | 223646 | 0.160 |
Why?
|
Quality Improvement | 1 | 2014 | 3857 | 0.150 |
Why?
|
Policy | 1 | 2022 | 513 | 0.150 |
Why?
|
Mutation | 7 | 2021 | 30238 | 0.150 |
Why?
|
Survival Rate | 7 | 2020 | 12840 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.150 |
Why?
|
BRCA1 Protein | 2 | 2024 | 1155 | 0.140 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2020 | 410 | 0.140 |
Why?
|
Biomedical Research | 3 | 2013 | 3463 | 0.140 |
Why?
|
Neutropenia | 2 | 2017 | 892 | 0.140 |
Why?
|
Appointments and Schedules | 2 | 2014 | 443 | 0.130 |
Why?
|
Colonoscopy | 1 | 2024 | 1409 | 0.130 |
Why?
|
Treatment Outcome | 23 | 2021 | 65371 | 0.130 |
Why?
|
Breast | 5 | 2023 | 1976 | 0.130 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2022 | 631 | 0.130 |
Why?
|
Ticlopidine | 1 | 2000 | 730 | 0.120 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2021 | 640 | 0.120 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1406 | 0.120 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 581 | 0.120 |
Why?
|
Hospice Care | 1 | 2022 | 678 | 0.120 |
Why?
|
Interinstitutional Relations | 2 | 2007 | 235 | 0.120 |
Why?
|
Imidazoles | 2 | 2017 | 1169 | 0.120 |
Why?
|
Aged, 80 and over | 16 | 2024 | 59629 | 0.120 |
Why?
|
Stomatitis | 1 | 2017 | 271 | 0.120 |
Why?
|
Follow-Up Studies | 15 | 2020 | 39348 | 0.110 |
Why?
|
Nurse Practitioners | 1 | 2017 | 271 | 0.110 |
Why?
|
Community-Institutional Relations | 1 | 2015 | 209 | 0.110 |
Why?
|
Bone Marrow Neoplasms | 1 | 2014 | 101 | 0.110 |
Why?
|
Boston | 4 | 2021 | 9374 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 629 | 0.110 |
Why?
|
Prospective Studies | 12 | 2024 | 54926 | 0.110 |
Why?
|
Organizational Affiliation | 1 | 2013 | 34 | 0.110 |
Why?
|
Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2024 | 10399 | 0.110 |
Why?
|
Cell Cycle | 2 | 2020 | 2932 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2011 | 4055 | 0.100 |
Why?
|
Stroke Volume | 4 | 2018 | 5622 | 0.100 |
Why?
|
Health Policy | 2 | 2015 | 2698 | 0.100 |
Why?
|
Drug Administration Schedule | 5 | 2019 | 4860 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2020 | 10760 | 0.100 |
Why?
|
Pilot Projects | 5 | 2023 | 8741 | 0.100 |
Why?
|
Amenorrhea | 1 | 2015 | 484 | 0.090 |
Why?
|
Receptors, Androgen | 1 | 2018 | 1089 | 0.090 |
Why?
|
Indoles | 2 | 1990 | 1836 | 0.090 |
Why?
|
Time Factors | 7 | 2019 | 40218 | 0.090 |
Why?
|
Terminal Care | 2 | 2022 | 1770 | 0.090 |
Why?
|
Massachusetts | 2 | 2019 | 8890 | 0.090 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 427 | 0.090 |
Why?
|
Universities | 2 | 2008 | 1005 | 0.090 |
Why?
|
Survival Analysis | 7 | 2019 | 10101 | 0.090 |
Why?
|
Program Evaluation | 1 | 2019 | 2507 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6526 | 0.090 |
Why?
|
Medicaid | 2 | 2014 | 2840 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2062 | 0.090 |
Why?
|
Income | 1 | 2019 | 1878 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8748 | 0.090 |
Why?
|
Medicare | 2 | 2022 | 6809 | 0.090 |
Why?
|
Guidelines as Topic | 1 | 2016 | 1397 | 0.090 |
Why?
|
Radiation Oncology | 1 | 2016 | 572 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1829 | 0.080 |
Why?
|
Phthalazines | 2 | 2024 | 397 | 0.080 |
Why?
|
Leucomycins | 1 | 1989 | 3 | 0.080 |
Why?
|
Lymph Nodes | 3 | 2019 | 3474 | 0.080 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2007 | 1627 | 0.080 |
Why?
|
Diarrhea | 2 | 2020 | 1320 | 0.080 |
Why?
|
Retreatment | 2 | 2021 | 598 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2024 | 6974 | 0.080 |
Why?
|
Health Care Surveys | 2 | 2018 | 2434 | 0.080 |
Why?
|
Choice Behavior | 2 | 2019 | 848 | 0.080 |
Why?
|
Disease Progression | 2 | 2023 | 13671 | 0.080 |
Why?
|
Double-Blind Method | 5 | 2023 | 12465 | 0.080 |
Why?
|
Aspirin | 1 | 2020 | 3135 | 0.080 |
Why?
|
Ventricular Function, Left | 3 | 2018 | 3941 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2000 | 2763 | 0.070 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2008 | 131 | 0.070 |
Why?
|
Breast Neoplasms, Male | 2 | 2020 | 213 | 0.070 |
Why?
|
History, 21st Century | 1 | 2014 | 1573 | 0.070 |
Why?
|
Cyclophosphamide | 4 | 2022 | 2227 | 0.070 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9263 | 0.070 |
Why?
|
Psychometrics | 2 | 2014 | 3063 | 0.070 |
Why?
|
Advance Directives | 1 | 2009 | 249 | 0.070 |
Why?
|
Nausea | 2 | 2020 | 682 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36743 | 0.070 |
Why?
|
Tobacco Industry | 1 | 2008 | 138 | 0.070 |
Why?
|
Risk Assessment | 6 | 2020 | 24315 | 0.070 |
Why?
|
Melanoma, Experimental | 1 | 1990 | 559 | 0.070 |
Why?
|
Financing, Organized | 1 | 2008 | 203 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 662 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5341 | 0.070 |
Why?
|
Telemedicine | 1 | 2023 | 3109 | 0.060 |
Why?
|
Antigens, Neoplasm | 2 | 2024 | 1997 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14783 | 0.060 |
Why?
|
Retrospective Studies | 12 | 2023 | 81762 | 0.060 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3948 | 0.060 |
Why?
|
Drug Costs | 1 | 2014 | 1195 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 8647 | 0.060 |
Why?
|
Genotype | 4 | 2023 | 13045 | 0.060 |
Why?
|
Societies, Medical | 1 | 2017 | 3968 | 0.060 |
Why?
|
Social Values | 1 | 2006 | 224 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1989 | 681 | 0.060 |
Why?
|
Organizational Policy | 1 | 2007 | 435 | 0.060 |
Why?
|
Heart Diseases | 2 | 2009 | 2819 | 0.060 |
Why?
|
Drug Resistance | 2 | 1990 | 1599 | 0.060 |
Why?
|
Spouse Abuse | 1 | 2006 | 182 | 0.060 |
Why?
|
Health Status Disparities | 1 | 2016 | 1885 | 0.060 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2145 | 0.060 |
Why?
|
Filgrastim | 3 | 2010 | 131 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 12543 | 0.060 |
Why?
|
Male | 14 | 2024 | 364719 | 0.060 |
Why?
|
Piperazines | 3 | 2020 | 2554 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Life Style | 1 | 2016 | 3932 | 0.060 |
Why?
|
Poverty | 1 | 2016 | 2720 | 0.060 |
Why?
|
Feasibility Studies | 4 | 2023 | 5315 | 0.060 |
Why?
|
Research Support as Topic | 1 | 2008 | 696 | 0.060 |
Why?
|
Occult Blood | 1 | 2024 | 199 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2009 | 2923 | 0.050 |
Why?
|
Continuity of Patient Care | 2 | 2021 | 1078 | 0.050 |
Why?
|
Attitude to Death | 1 | 2006 | 400 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4916 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 2007 | 1157 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Culture | 1 | 2006 | 622 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2019 | 1791 | 0.050 |
Why?
|
Prejudice | 1 | 2006 | 574 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 1 | 2008 | 1209 | 0.050 |
Why?
|
Cohort Studies | 6 | 2023 | 41754 | 0.050 |
Why?
|
Estrogens | 1 | 2008 | 1536 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 630 | 0.050 |
Why?
|
Adenosine Diphosphate | 1 | 2022 | 422 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1906 | 0.050 |
Why?
|
Erythropoietin | 1 | 2005 | 718 | 0.050 |
Why?
|
Reminder Systems | 1 | 2024 | 388 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2006 | 724 | 0.050 |
Why?
|
Schools, Medical | 1 | 2007 | 883 | 0.050 |
Why?
|
Gastroesophageal Reflux | 1 | 2008 | 836 | 0.050 |
Why?
|
Costs and Cost Analysis | 2 | 2018 | 1667 | 0.040 |
Why?
|
Gene Amplification | 2 | 2019 | 1095 | 0.040 |
Why?
|
Receptor, erbB-3 | 1 | 2021 | 142 | 0.040 |
Why?
|
Blood-Brain Barrier | 1 | 2007 | 1034 | 0.040 |
Why?
|
Mammaplasty | 1 | 2011 | 1268 | 0.040 |
Why?
|
Administration, Oral | 2 | 2019 | 4030 | 0.040 |
Why?
|
SEER Program | 2 | 2016 | 1444 | 0.040 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 26379 | 0.040 |
Why?
|
Focus Groups | 1 | 2006 | 1460 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 330 | 0.040 |
Why?
|
Data Collection | 1 | 2009 | 3327 | 0.040 |
Why?
|
Risk Factors | 6 | 2022 | 74944 | 0.040 |
Why?
|
Plasmapheresis | 1 | 2000 | 206 | 0.040 |
Why?
|
Carcinoma | 1 | 2011 | 2332 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 13014 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1737 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3858 | 0.040 |
Why?
|
Doxorubicin | 4 | 2010 | 2234 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 667 | 0.040 |
Why?
|
Polyethylene Glycols | 3 | 2010 | 1196 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3620 | 0.040 |
Why?
|
Insurance Coverage | 2 | 2021 | 1946 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1613 | 0.040 |
Why?
|
Endometrial Neoplasms | 1 | 2007 | 1382 | 0.040 |
Why?
|
Radiotherapy | 2 | 2015 | 1502 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 506 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6395 | 0.030 |
Why?
|
Chromatin | 1 | 1989 | 2981 | 0.030 |
Why?
|
Clodronic Acid | 1 | 2017 | 60 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2521 | 0.030 |
Why?
|
Prescription Fees | 1 | 2018 | 153 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2019 | 2954 | 0.030 |
Why?
|
Vomiting | 1 | 2020 | 655 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 2663 | 0.030 |
Why?
|
Pyridines | 2 | 2019 | 2894 | 0.030 |
Why?
|
Abdominal Neoplasms | 1 | 2018 | 287 | 0.030 |
Why?
|
Professional Practice Location | 1 | 2016 | 57 | 0.030 |
Why?
|
Patient Compliance | 1 | 2006 | 2697 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1514 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2023 | 1422 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2000 | 893 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3269 | 0.030 |
Why?
|
Fasting | 1 | 2022 | 1610 | 0.030 |
Why?
|
Recurrence | 2 | 2019 | 8509 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 17140 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1652 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2025 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2300 | 0.030 |
Why?
|
DNA | 1 | 1989 | 7214 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3284 | 0.030 |
Why?
|
Craniotomy | 1 | 2019 | 736 | 0.030 |
Why?
|
Communication | 1 | 2009 | 3905 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1557 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2010 | 6514 | 0.030 |
Why?
|
Databases, Factual | 3 | 2015 | 8080 | 0.030 |
Why?
|
Purines | 1 | 2017 | 615 | 0.030 |
Why?
|
Central Nervous System | 1 | 2021 | 1346 | 0.030 |
Why?
|
Ownership | 1 | 2016 | 338 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 580 | 0.030 |
Why?
|
Japan | 1 | 2017 | 1418 | 0.030 |
Why?
|
Socioeconomic Factors | 3 | 2018 | 7852 | 0.030 |
Why?
|
Age Factors | 4 | 2017 | 18412 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 716 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2018 | 1105 | 0.030 |
Why?
|
Young Adult | 5 | 2018 | 60066 | 0.030 |
Why?
|
Drug Interactions | 1 | 2017 | 1419 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9538 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2017 | 864 | 0.020 |
Why?
|
Mental Health | 1 | 2006 | 3275 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4120 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2359 | 0.020 |
Why?
|
Comorbidity | 1 | 2006 | 10590 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1388 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1495 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2022 | 16045 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2914 | 0.020 |
Why?
|
Nogalamycin | 1 | 1990 | 2 | 0.020 |
Why?
|
Leukemia P388 | 1 | 1990 | 14 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2945 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3620 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1008 | 0.020 |
Why?
|
Models, Biological | 1 | 2006 | 9495 | 0.020 |
Why?
|
Social Support | 1 | 2020 | 2193 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2271 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2230 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2040 | 0.020 |
Why?
|
Sirolimus | 1 | 2017 | 1540 | 0.020 |
Why?
|
Cardiac Electrophysiology | 1 | 2009 | 60 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2006 | 4423 | 0.020 |
Why?
|
Circular Dichroism | 1 | 1989 | 337 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9669 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13290 | 0.020 |
Why?
|
Stents | 1 | 2000 | 3195 | 0.020 |
Why?
|
Karyotyping | 1 | 1990 | 1177 | 0.020 |
Why?
|
Chief Executive Officers, Hospital | 1 | 2007 | 9 | 0.020 |
Why?
|
Adolescent | 4 | 2021 | 89169 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3671 | 0.020 |
Why?
|
Nonprescription Drugs | 1 | 2008 | 119 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1969 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1703 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3800 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9613 | 0.020 |
Why?
|
Sodium Chloride | 1 | 1989 | 584 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2661 | 0.020 |
Why?
|
Incidence | 2 | 2015 | 21538 | 0.020 |
Why?
|
Palliative Care | 1 | 2022 | 3643 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2540 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22291 | 0.020 |
Why?
|
Registries | 2 | 2017 | 8375 | 0.020 |
Why?
|
Cell Division | 2 | 1990 | 4473 | 0.020 |
Why?
|
Biological Transport | 1 | 1990 | 2085 | 0.020 |
Why?
|
Child | 1 | 2014 | 80917 | 0.020 |
Why?
|
Goals | 1 | 2011 | 717 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2017 | 3488 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 20760 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8542 | 0.010 |
Why?
|
Gift Giving | 1 | 2004 | 76 | 0.010 |
Why?
|
Hospitalization | 1 | 2023 | 10840 | 0.010 |
Why?
|
Cell Survival | 2 | 1990 | 5777 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1741 | 0.010 |
Why?
|
Cultural Characteristics | 1 | 2004 | 250 | 0.010 |
Why?
|
Administrative Personnel | 1 | 2004 | 185 | 0.010 |
Why?
|
Mice | 4 | 2018 | 82029 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1990 | 6124 | 0.010 |
Why?
|
Kinetics | 1 | 1990 | 6329 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3706 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4057 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26422 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12077 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3591 | 0.010 |
Why?
|
Faculty | 1 | 2004 | 383 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 575 | 0.010 |
Why?
|
Body Mass Index | 2 | 2008 | 13053 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6874 | 0.010 |
Why?
|
Faculty, Medical | 1 | 2007 | 1226 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2479 | 0.010 |
Why?
|
Histones | 1 | 1989 | 2601 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15869 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6793 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6340 | 0.010 |
Why?
|
Animals | 4 | 2018 | 169246 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 18065 | 0.010 |
Why?
|
Educational Status | 1 | 2004 | 2515 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2004 | 2741 | 0.010 |
Why?
|
Cell Line | 1 | 1990 | 15597 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20227 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23645 | 0.010 |
Why?
|
Brain | 1 | 2019 | 27360 | 0.010 |
Why?
|
Menogaril | 1 | 1990 | 4 | 0.010 |
Why?
|
Verapamil | 1 | 1990 | 242 | 0.010 |
Why?
|
Glutathione | 1 | 1990 | 589 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 2004 | 15454 | 0.000 |
Why?
|
Drug Synergism | 1 | 1990 | 1760 | 0.000 |
Why?
|
Algorithms | 1 | 2005 | 14164 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1990 | 19015 | 0.000 |
Why?
|